Merck to invest up to $1 billion in Google Cloud AI partnership

Merck is betting up to $1 billion that artificial intelligence can do more than shave minutes off office tasks. The drugmaker’s new partnership with Google Cloud is aimed at embedding AI across research and development, manufacturing, commercial work and corporate functions, a sign that one of the world’s biggest pharmaceutical companies wants measurable gains in speed, cost and compliance rather than another pilot project.

The companies said the multi-year investment will fund AI infrastructure, engineers and licensing for Google’s Gemini Enterprise platform, with Google Cloud staff working alongside Merck teams. Merck said the effort is designed to deploy an agentic platform across its operations and to help digitize data for its 75,000 employees worldwide. That scale matters. In a business where a single delayed filing or production bottleneck can cost millions, the value case for AI will be judged less on novelty than on whether it shortens development cycles, lowers administrative overhead and helps more drugs move through the pipeline.

Merck is not starting from zero. The company said it has already used Google technology for roughly two years to help prepare parts of clinical study reports, and that the tools have cut by half the time and cost needed to compile reimbursement dossiers in many countries. Those are not abstract productivity claims. Clinical study reports and reimbursement packages are central to whether a drug reaches regulators, payers and patients quickly enough to matter commercially. If Google’s systems can reliably compress that work, Merck could gain an edge in both launch timing and operating efficiency.

The unanswered question is whether those gains can extend beyond document preparation into harder problems inside pharma. Merck said the collaboration will touch drug research, regulatory work, manufacturing and commercial operations, including computerized simulations of lab experiments and faster regulatory submissions. That puts the deal in a different category from the industry’s many AI experiments, because it ties investment directly to the work that determines whether a medicine succeeds or stalls. Dave Williams, Merck’s chief information and digital officer, said the company could easily imagine investing a billion dollars over the next several years and expects the collaboration to last at least a decade.

Google Cloud is making a similar bet on enterprise AI adoption. Gemini Enterprise launched in October 2025 as Google’s workplace AI platform, and Google Cloud also announced a separate $750 million fund for partners at Cloud Next in Las Vegas. For Google, the Merck deal is a test of whether its AI stack can prove itself in a highly regulated industry where promised gains must survive scrutiny from scientists, manufacturers, payers and regulators alike.